Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
people with obesity, in this paper
Among Japanese participants with obesity and type 2 diabetes (T2D) from SURMOUNT-2 trial, the trial randomly assignedassigned by chance
tirzepatide 10 mg
placebo
Reported lower percent change in body weight from baseline to week 72, no range given−12.4
randomisedAmong Japanese participants with obesity and type 2 diabetes (T2D) from SURMOUNT-2 trial, the trial randomly assignedassigned by chance
tirzepatide 15 mg
placebo
Reported lower percent change in body weight from baseline to week 72, no range given−10.2
randomisedthe abstract, start to end
… 15 mg (p = 0.013) compared with placebo: -12.4% (1.8%) and -10.2% (1.8%), respectively, compared …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Mean percent change in body weight from baseline to week 72tirzepatide 10 mg vs placebo, in Japanese participants with obesity and type 2 diabetes (T2D) from SURMOUNT-2 trial
−12.4
Mean percent change in body weight from baseline to week 72tirzepatide 15 mg vs placebo, in Japanese participants with obesity and type 2 diabetes (T2D) from SURMOUNT-2 trial
−10.2
GIP/GLP-1 & amylin agonistsBody weight & composition
GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated
unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
1 / 6